Exploring the Benefit/Risk Associated With Antiangiogenic Agents for the Treatment of Non–Small Cell Lung Cancer Patients

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-16-1968
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Potential Antiangiogenic Treatment Eligibility of Patients With Squamous Non-Small–Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01)

Cancer Management and Research
Oncology
2019English

Quantifying the Benefit of Non-Small-Cell Lung Cancer Immunotherapy

The Lancet
Medicine
2019English

Immunotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2019English

Bevacizumab for the Treatment of Non-Small Cell Lung Cancer Patients With Synchronous Brain Metastases

Scientific Reports
Multidisciplinary
2019English

Gefitinib for the Treatment of Non-Small-Cell Lung Cancer

Expert Opinion on Pharmacotherapy
MedicinePharmacology
2010English

Cost Effectiveness of Treatment With New Agents in Advanced Non-Small-Cell Lung Cancer

PharmacoEconomics
Health PolicyPublic HealthOccupational HealthPharmacologyEnvironmental
2012English

Quantifying the Benefit of Non-Small-Cell Lung Cancer Immunotherapy – Authors' Reply

The Lancet
Medicine
2019English

MA14.11 Factors Associated With Early Mortality in Non-Small Cell Lung Cancer Patients Following Systemic Anti-Cancer Treatment

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

On the Pharmacogenetics of Non-Small Cell Lung Cancer Treatment

Expert Opinion on Drug Metabolism and Toxicology
MedicineToxicologyPharmacology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy